Dr. Yu Yang 杨雨
Chief Physician
Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of liver cancer, biliary tract tumors, gastrointestinal tumors, and reproductive system tumors.
Dr. Yang is a Chief Physician, Level 1 Expert, and Master’s Supervisor at West China Hospital, Sichuan University.
Professional roles
- Member, Internal Medicine Group, Liver Cancer Professional Committee, Chinese Medical Doctor Association
- Member, Liver Cancer Professional Committee, Sichuan Oncology Society
- Member, Anti-cancer Drug Professional Committee, Sichuan Anti-Cancer Association
Name order: in Chinese the family name comes first (Yang Yu). Papers usually list the name as Yu Yang or Yang Y.
Selected publications
116 papers on PubMed matched by name and affiliation; 20 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cell Biochem, 2026 (first author): Trehalose alleviates oxidative stress-induced senescence and is associated with cell-cycle remodeling. PubMed 42955531
- Front Immunol, 2026 (senior author): Gefitinib-based therapy in refractory hepatocellular carcinoma with EGFR overexpression: a spatial profiling-guided case report. PubMed 42865658
- Front Immunol, 2026 (senior author): Unlocking HER2 as a target in KRAS-mutated rectal cancer: a case of significant response to zanidatamab-based regimen. PubMed 42688229
- Eur J Med Chem, 2025 (first author): Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia. PubMed 40578254
- Liver Cancer, 2025 (first author): Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition). PubMed 40547957
- Front Pharmacol, 2025 (senior author): Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach. PubMed 40235542
- Front Immunol, 2025 (senior author): Case Report: Multiple cutaneous keratoacanthoma-like lesions in a colorectal cancer patient treated with sintilimab. PubMed 40098970
- Front Immunol, 2025 (first author): Single-cell RNA-sequencing reveals cellular heterogeneity and immune microenvironment characteristics between ocular adnexal mucosa-associated lymphoid lymphoma and IgG4-related ophthalmic disease. PubMed 40078987
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion